Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Volitionrx (VNRX) Current Deferred Revenue (2021 - 2025)

Historic Current Deferred Revenue for Volitionrx (VNRX) over the last 5 years, with Q3 2025 value amounting to $354000.0.

  • Volitionrx's Current Deferred Revenue fell 9845.37% to $354000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $354000.0, marking a year-over-year decrease of 9845.37%. This contributed to the annual value of $230000.0 for FY2024, which is 9900.0% down from last year.
  • As of Q3 2025, Volitionrx's Current Deferred Revenue stood at $354000.0, which was down 9845.37% from $122441.0 recorded in Q2 2025.
  • Over the past 5 years, Volitionrx's Current Deferred Revenue peaked at $12.5 billion during Q4 2021, and registered a low of $122441.0 during Q2 2025.
  • Its 5-year average for Current Deferred Revenue is $792.2 million, with a median of $10.0 million in 2022.
  • Its Current Deferred Revenue has fluctuated over the past 5 years, first crashed by 9992.01% in 2022, then surged by 13000.0% in 2023.
  • Volitionrx's Current Deferred Revenue (Quarter) stood at $12.5 billion in 2021, then crashed by 99.92% to $10.0 million in 2022, then surged by 130.0% to $23.0 million in 2023, then tumbled by 99.0% to $230000.0 in 2024, then surged by 53.91% to $354000.0 in 2025.
  • Its Current Deferred Revenue stands at $354000.0 for Q3 2025, versus $122441.0 for Q2 2025 and $230000.0 for Q1 2025.